MedTrace Logo

A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4%

NCT00151541 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 301

Last updated 2011-05-30

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and efficacy of 5% Dapsone Topical Gel, (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. The second objective of the study is to determine dapsone exposure after co-administration of DTG 5% with vehicle control, adapalene or benzoyl peroxide gel.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Dapsone Topical Gel + adapalene gel 0.1%

DRUG

Dapsone Topical Gel + benzoyl peroxide gel 4%

DRUG

Dapsone Topical Gel + vehicle control

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Steven Garrett, MS, DDS, FACS · QLT USA, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2005-07-31
Completion
2005-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00151541 on ClinicalTrials.gov